TriangleGlofitamab (NCT06043674)
Glofitamab trial for Chronic Lymphocytic Leukemia (NCT06043674). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has transformed into large B-cell lymphoma. Previous treatment determines the eligible cohort.
The idea: after obinutuzumab, intravenous glofitamab links T cells to CD20-bearing lymphoma cells. Cohorts test glofitamab alone, or with polatuzumab vedotin, pirtobrutinib or atezolizumab. The pirtobrutinib group requires untreated transformation and previous BTK-inhibitor exposure; atezolizumab requires relapsed or refractory transformation. Early doses require hospital monitoring.
This phase 2 study plans 70 patients. Christine Ryan leads at Dana-Farber in Boston, with five recruiting US sites. Cohort opening is sequential.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.